Loading
Chemokine Receptors and Signaling · Journal article
Frontiers in Pharmacology · September 4, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review of CXCR4-targeted radiotheranostic design principles, highlighting structural modifications that optimize receptor affinity and pharmacokinetics. It summarizes preclinical structure-activity relationships and notes that Pentixafor/Pentixather has entered early-stage clinical evaluation, but provides no new efficacy data, trial outcomes, or comparative evidence.
Journal article. Broad pathological conditions including cancer, cardiovascular disorders, infectious and autoimmune diseases; no specific patient cohort studied in this review..
CXCR4 is identified as a promising target for molecular imaging and therapy across cancer, cardiovascular, infectious, and autoimmune diseases Peptide-based theranostic pair Pentixafor/Pentixather has advanced into early-stage clinical evaluations for imaging and therapy CXCR4 crystal structures and structure-activity relationship studies have accelerated design of novel CXCR4-targeted radiopharmaceuticals
No quantitative efficacy, safety, or pharmacokinetic data reported CXCR4 crystal structures and structure-activity relationship studies have accelerated design of novel CXCR4-targeted radiopharmaceuticals
The source did not state who this applies to in practice.
A narrative review synthesizing preclinical structure-activity data and early-stage clinical experience to propose design principles for CXCR4 radiotheranostics; no new primary data or comparative efficacy evidence is reported.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Radiotheranostic agents enable paired diagnostic imaging and targeted radiopharmaceutical therapy through the selection of appropriate radioisotopes. Radiotheranostics are typically composed of a targeting vector, a chelator or prosthetic group for radiolabeling and an optional linker for optimizing their pharmacokinetic properties. The chemokine receptor 4 (CXCR4) is a promising target for molecular imaging and therapy across a broad range of pathological conditions, including cancer, cardiovascular disorders, infectious and autoimmune diseases. The elucidation of CXCR4 crystal structures, together with extensive structure-activity relationship studies, has accelerated the design of novel small molecule and peptide-based CXCR4-targeted radiopharmaceuticals. These molecules have served as scaffolds that can be chemically modified to optimize their pharmacokinetic properties and maximize accumulation at the target organ. In oncology, the peptide-based theranostic pair Pentixafor/Pentixather has advanced into early-stage clinical evaluations for imaging and therapy. This review summarizes the current landscape of CXCR4 radiopharmaceuticals, and highlights key structural features and chemical modifications that lead to enhanced receptor affinity as well as improved pharmacokinetic and in vivo targeting properties for theranostic applications.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.